Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2024.053363
Journal Menu
Special Issues
Table of Content

All issues

Online First

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

ARTICLE

A Nomogram for Predicting Survival for Patients with Brain Metastatic and EGFR Mutation Advanced Non-Small Cell Lung Cancer

JIYUN PANG1,2,#, WEIGANG XIU1,#, YUEYUN CHEN4, WENJING LIAO1,2, QIN ZHANG3,*, HUASHAN SHI4,*
1 Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China
2 West China School of Medicine, Sichuan University, Chengdu, 610041, China
3 West China School of Medicine, Department of Postgraduate Students, Sichuan University, Chengdu, 610041, China
4 Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China
* Corresponding Author: QIN ZHANG. Email: email; HUASHAN SHI. Email: email
# Contributed equally to this study

Oncology Research https://doi.org/10.32604/or.2024.053363

Received 29 April 2024; Accepted 05 August 2024; Published online 13 September 2024

Abstract

Background: Non-small cell lung cancer (NSCLC) is often accompanied by brain metastasis (BM), and the prognosis of patients with BM is poor. This study assesses the prognostic impact of BM in NSCLC patients with epidermal growth factor receptor (EGFR) mutations. Methods: We retrospectively evaluated 692 advanced NSCLC patients with EGFR mutations treated with tyrosine kinase inhibitors (TKIs) at West China Hospital from 2015 to 2019. The overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), disease control rate (DCR), and clinical parameters of the BM and non-BM groups were compared. Univariable and multivariable regressions were performed to identify independent prognostic factors, followed by validation of a predictive nomogram using receiver operating characteristics and calibration curves. Immune infiltration in tumor tissues was assessed by immunostaining. Results: NSCLC patients with BM exhibited a higher frequency of other-site and multi-organ metastases than those without BM. The BM group demonstrated significantly worse OS (26.2 vs. 39.1 months, p < 0.001) and PFS (12.3 vs. 18.8 months, p < 0.001), although the DCR (p = 0.831) and ORR (p = 0.653) were similar in both groups. BM was identified as an independent predictor of poor prognosis. The nomogram performed well, achieving a C index of 0.73, with consistent calibration curves for predicted and actual prognoses. Additionally, fewer peripheral lymphocytes were observed in the BM group. Conclusions: BM is a significant risk factor for NSCLC patients, potentially linked to lymphocytopenia.

Keywords

Brain metastasis (BM); Epidermal growth factor receptor (EGFR); Tyrosine kinase inhibitor (TKI); Tumor microenvironment; Non-small cell lung cancer (NSCLC)

  • 209

    View

  • 26

    Download

  • 0

    Like

Related articles
Copyright© 2024 Tech Science Press
© 1997-2024 TSP (Henderson, USA) unless otherwise stated

Share Link